JG
EIGR

Jefferies Group’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Jefferies Group’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-18
Closed -$153K – 3543
2015
Q1 		$153K Buy
+18
New +$157K ﹤0.01% 1819

Other funds holding EIGR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Jefferies Group's EIGR Position: Q2 2019 in Review

Jefferies Group sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2019, closing a stake of 390 shares — an estimated $164K sold.

Jefferies Group first reported a position in EIGR in Q1 2019 and held it in 1 quarter. The position peaked at $164K in Q1 2019. 78 funds tracked by Wall St. Rank hold EIGR as of Q2 2019.

  • Jefferies Group reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
  • Jefferies Group sold 390 Eiger BioPharmaceuticals, Inc. shares in Q2 2019, an estimated $164K.
  • Jefferies Group first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2019 and held it in 1 quarter.
  • Jefferies Group's Eiger BioPharmaceuticals, Inc. position peaked at $164K in Q1 2019.
  • 78 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2019.

Based on Jefferies Group's 13F filing for Q2 2019, filed 14 Aug 2019.